Matthew P. Goetz
Breast oncologist who led MONARCH 3 and studies how genetics shapes response to endocrine therapy.
Medical oncologist and pharmacologist; principal investigator of MONARCH 3 (abemaciclib first line) and of tamoxifen pharmacogenomics work. Co-leads the breast cancer programme at Mayo Clinic.
| Title | Journal | Year |
|---|---|---|
| MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer | Journal of Clinical Oncology | 2017 |
| Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3 | Annals of Oncology | 2024 |
Pages like this
not linked directly; found by shared links- TrialpostMONARCH
Shares Abemaciclib, CDK4/6, HR-positive / HER2-negative breast cancer.
- TrialEMBER-3
Shares Abemaciclib, CDK4/6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- TrialMONALEESA-2
Shares CDK4/6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- PersonDebu Tripathy
Shares CDK4/6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- IdeaCDK4-selective inhibitors as the new first-line backbone
Shares Abemaciclib, CDK4/6, HR-positive / HER2-negative breast cancer.
- TriallidERA
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- TrialPALOMA-2
- TrialFOURLIGHT-1